When it comes to immunotherapy, there is much preclinical evidence that BAP1 is associated with an immunosuppressive microenvironment: it has been demonstrated that BAP1 mutation is associated with T-cell suppression in preclinical RCC models [52]. This evidence concerns the gene BAP1 and renal cell carcinoma.